(4S)-5-[[(1S)-1-Carboxy-2-cyclohexylethyl]amino]-4-[[(2S)-2-[[(3R)-4-cyclohexyl-2-oxo-3-(phenylmethoxycarbonylamino)butanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- (4S)-5-[[(1S)-1-Carboxy-2-cyclohexylethyl]amino]-4-[[(2S)-2-[[(3R)-4-cyclohexyl-2-oxo-3-(phenylmethoxycarbonylamino)butanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid
- DrugBank Accession Number
- DB01984
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 771.9001
Monoisotopic: 771.416691079 - Chemical Formula
- C38H57N7O10
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Oligopeptides
- Alternative Parents
- Glutamic acid and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Benzyloxycarbonyls / Carbocyclic fatty acids / N-acyl amines / Dicarboxylic acids and derivatives / Carbamate esters / Secondary carboxylic acid amides / Ketones show 6 more
- Substituents
- Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Aromatic homomonocyclic compound / Benzenoid / Benzyloxycarbonyl / Carbamic acid ester / Carbocyclic fatty acid / Carbonyl group / Carboxamide group show 23 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- LKCWMWZIRUHWBW-ZXYZSCNASA-N
- InChI
- InChI=1S/C38H57N7O10/c39-37(40)41-20-10-17-27(33(49)42-28(18-19-31(46)47)34(50)44-30(36(52)53)22-25-13-6-2-7-14-25)43-35(51)32(48)29(21-24-11-4-1-5-12-24)45-38(54)55-23-26-15-8-3-9-16-26/h3,8-9,15-16,24-25,27-30H,1-2,4-7,10-14,17-23H2,(H,42,49)(H,43,51)(H,44,50)(H,45,54)(H,46,47)(H,52,53)(H4,39,40,41)/t27-,28-,29+,30-/m0/s1
- IUPAC Name
- (4S)-4-[(2S)-2-[(3R)-3-{[(benzyloxy)carbonyl]amino}-4-cyclohexyl-2-oxobutanamido]-5-[(diaminomethylidene)amino]pentanamido]-4-{[(1S)-1-carboxy-2-cyclohexylethyl]carbamoyl}butanoic acid
- SMILES
- NC(N)=NCCC[C@H](NC(=O)C(=O)[C@@H](CC1CCCCC1)NC(=O)OCC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1CCCCC1)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 17753951
- PubChem Substance
- 46507473
- ChemSpider
- 16743946
- ZINC
- ZINC000098208801
- PDBe Ligand
- DKT
- PDB Entries
- 1n6f
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0106 mg/mL ALOGPS logP 1.37 ALOGPS logP 1.2 Chemaxon logS -4.9 ALOGPS pKa (Strongest Acidic) 3.27 Chemaxon pKa (Strongest Basic) 10.76 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 12 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 281.7 Å2 Chemaxon Rotatable Bond Count 23 Chemaxon Refractivity 198.69 m3·mol-1 Chemaxon Polarizability 82.45 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.7293 Blood Brain Barrier - 0.7584 Caco-2 permeable - 0.7531 P-glycoprotein substrate Substrate 0.7489 P-glycoprotein inhibitor I Non-inhibitor 0.6091 P-glycoprotein inhibitor II Inhibitor 0.5146 Renal organic cation transporter Non-inhibitor 0.7011 CYP450 2C9 substrate Non-substrate 0.7592 CYP450 2D6 substrate Non-substrate 0.7881 CYP450 3A4 substrate Non-substrate 0.6506 CYP450 1A2 substrate Non-inhibitor 0.8277 CYP450 2C9 inhibitor Non-inhibitor 0.871 CYP450 2D6 inhibitor Non-inhibitor 0.8678 CYP450 2C19 inhibitor Non-inhibitor 0.8241 CYP450 3A4 inhibitor Non-inhibitor 0.7967 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9116 Ames test Non AMES toxic 0.575 Carcinogenicity Non-carcinogens 0.9203 Biodegradation Not ready biodegradable 0.8459 Rat acute toxicity 2.4223 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9765 hERG inhibition (predictor II) Inhibitor 0.5533
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 253.51854 predictedDeepCCS 1.0 (2019) [M+H]+ 255.91411 predictedDeepCCS 1.0 (2019) [M+Na]+ 261.9064 predictedDeepCCS 1.0 (2019)
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52